A current review of COVID-19 for the cardiovascular specialist.
Identifieur interne : 000185 ( Main/Corpus ); précédent : 000184; suivant : 000186A current review of COVID-19 for the cardiovascular specialist.
Auteurs : Joshua P. Lang ; Xiaowen Wang ; Filipe A. Moura ; Hasan K. Siddiqi ; David A. Morrow ; Erin A. BohulaSource :
- American heart journal [ 1097-6744 ] ; 2020.
Abstract
Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system. Cardiovascular risk factors and chronic cardiovascular conditions are prevalent among patients affected by COVID-19 and associated with adverse outcomes. However, whether pre-existing cardiovascular disease is an independent determinant of higher mortality risk with COVID-19 remains uncertain. Acute cardiac injury, manifest by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, occurs in up to ~60% of hospitalized patients with severe COVID-19. Potential contributors to acute cardiac injury in the setting of COVID-19 include (1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; (2) acute coronary syndrome due to acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (3) microvascular dysfunction due to diffuse microthrombi or vascular injury; (4) stress-related cardiomyopathy (Takotsubo syndrome); (5) nonischemic myocardial injury due to a hyperinflammatory cytokine storm; or (6) direct viral cardiomyocyte toxicity and myocarditis. Diffuse thrombosis is emerging as an important contributor to adverse outcomes in patients with COVID-19. Practitioners should be vigilant for cardiovascular complications of COVID-19. Monitoring may include serial cardiac troponin and natriuretic peptides, along with fibrinogen, D-dimer, and inflammatory biomarkers. Management decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative nonischemic causes of injury, integrating the level of suspicion for COVID-19.
DOI: 10.1016/j.ahj.2020.04.025
PubMed: 32497913
PubMed Central: PMC7252118
Links to Exploration step
pubmed:32497913Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A current review of COVID-19 for the cardiovascular specialist.</title><author><name sortKey="Lang, Joshua P" sort="Lang, Joshua P" uniqKey="Lang J" first="Joshua P" last="Lang">Joshua P. Lang</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Xiaowen" sort="Wang, Xiaowen" uniqKey="Wang X" first="Xiaowen" last="Wang">Xiaowen Wang</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Moura, Filipe A" sort="Moura, Filipe A" uniqKey="Moura F" first="Filipe A" last="Moura">Filipe A. Moura</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Siddiqi, Hasan K" sort="Siddiqi, Hasan K" uniqKey="Siddiqi H" first="Hasan K" last="Siddiqi">Hasan K. Siddiqi</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Morrow, David A" sort="Morrow, David A" uniqKey="Morrow D" first="David A" last="Morrow">David A. Morrow</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Critical Care Cardiology Section, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Bohula, Erin A" sort="Bohula, Erin A" uniqKey="Bohula E" first="Erin A" last="Bohula">Erin A. Bohula</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Critical Care Cardiology Section, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: ebohula@bwh.harvard.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32497913</idno><idno type="pmid">32497913</idno><idno type="doi">10.1016/j.ahj.2020.04.025</idno><idno type="pmc">PMC7252118</idno><idno type="wicri:Area/Main/Corpus">000185</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000185</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A current review of COVID-19 for the cardiovascular specialist.</title><author><name sortKey="Lang, Joshua P" sort="Lang, Joshua P" uniqKey="Lang J" first="Joshua P" last="Lang">Joshua P. Lang</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Xiaowen" sort="Wang, Xiaowen" uniqKey="Wang X" first="Xiaowen" last="Wang">Xiaowen Wang</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Moura, Filipe A" sort="Moura, Filipe A" uniqKey="Moura F" first="Filipe A" last="Moura">Filipe A. Moura</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Siddiqi, Hasan K" sort="Siddiqi, Hasan K" uniqKey="Siddiqi H" first="Hasan K" last="Siddiqi">Hasan K. Siddiqi</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Morrow, David A" sort="Morrow, David A" uniqKey="Morrow D" first="David A" last="Morrow">David A. Morrow</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Critical Care Cardiology Section, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Bohula, Erin A" sort="Bohula, Erin A" uniqKey="Bohula E" first="Erin A" last="Bohula">Erin A. Bohula</name><affiliation><nlm:affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Critical Care Cardiology Section, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: ebohula@bwh.harvard.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">American heart journal</title><idno type="eISSN">1097-6744</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system. Cardiovascular risk factors and chronic cardiovascular conditions are prevalent among patients affected by COVID-19 and associated with adverse outcomes. However, whether pre-existing cardiovascular disease is an independent determinant of higher mortality risk with COVID-19 remains uncertain. Acute cardiac injury, manifest by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, occurs in up to ~60% of hospitalized patients with severe COVID-19. Potential contributors to acute cardiac injury in the setting of COVID-19 include (1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; (2) acute coronary syndrome due to acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (3) microvascular dysfunction due to diffuse microthrombi or vascular injury; (4) stress-related cardiomyopathy (Takotsubo syndrome); (5) nonischemic myocardial injury due to a hyperinflammatory cytokine storm; or (6) direct viral cardiomyocyte toxicity and myocarditis. Diffuse thrombosis is emerging as an important contributor to adverse outcomes in patients with COVID-19. Practitioners should be vigilant for cardiovascular complications of COVID-19. Monitoring may include serial cardiac troponin and natriuretic peptides, along with fibrinogen, D-dimer, and inflammatory biomarkers. Management decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative nonischemic causes of injury, integrating the level of suspicion for COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32497913</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6744</ISSN><JournalIssue CitedMedium="Internet"><Volume>226</Volume><PubDate><Year>2020</Year><Month>May</Month><Day>03</Day></PubDate></JournalIssue><Title>American heart journal</Title><ISOAbbreviation>Am. Heart J.</ISOAbbreviation></Journal><ArticleTitle>A current review of COVID-19 for the cardiovascular specialist.</ArticleTitle><Pagination><MedlinePgn>29-44</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0002-8703(20)30133-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ahj.2020.04.025</ELocationID><Abstract><AbstractText>Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system. Cardiovascular risk factors and chronic cardiovascular conditions are prevalent among patients affected by COVID-19 and associated with adverse outcomes. However, whether pre-existing cardiovascular disease is an independent determinant of higher mortality risk with COVID-19 remains uncertain. Acute cardiac injury, manifest by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, occurs in up to ~60% of hospitalized patients with severe COVID-19. Potential contributors to acute cardiac injury in the setting of COVID-19 include (1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; (2) acute coronary syndrome due to acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (3) microvascular dysfunction due to diffuse microthrombi or vascular injury; (4) stress-related cardiomyopathy (Takotsubo syndrome); (5) nonischemic myocardial injury due to a hyperinflammatory cytokine storm; or (6) direct viral cardiomyocyte toxicity and myocarditis. Diffuse thrombosis is emerging as an important contributor to adverse outcomes in patients with COVID-19. Practitioners should be vigilant for cardiovascular complications of COVID-19. Monitoring may include serial cardiac troponin and natriuretic peptides, along with fibrinogen, D-dimer, and inflammatory biomarkers. Management decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative nonischemic causes of injury, integrating the level of suspicion for COVID-19.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Joshua P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaowen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>Filipe A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqi</LastName><ForeName>Hasan K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrow</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Critical Care Cardiology Section, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohula</LastName><ForeName>Erin A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Critical Care Cardiology Section, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: ebohula@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Heart J</MedlineTA><NlmUniqueID>0370465</NlmUniqueID><ISSNLinking>0002-8703</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32497913</ArticleId><ArticleId IdType="pii">S0002-8703(20)30133-2</ArticleId><ArticleId IdType="doi">10.1016/j.ahj.2020.04.025</ArticleId><ArticleId IdType="pmc">PMC7252118</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000185 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000185 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32497913
|texte= A current review of COVID-19 for the cardiovascular specialist.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32497913" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |